Risk Cmte. Member Furberg Is On Record Pro Long Trials, Con Pfizer Drugs
Executive Summary
FDA's new risk management subcommittee has a prominent and widely published member with strong predilections for long clinical trials showing clear clinical benefit, especially for follow-on compounds in an established class
You may also be interested in...
ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs
The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents
ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs
The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents
FDA Drug Safety Committee Inaugural Meeting Tentatively Set For April
The FDA Drug Safety & Risk Management Subcommittee's first official meeting is tentatively set for April 22-23